- Email: [email protected]
Combination therapy of cholinesterase inhibitor plus memantine for behavioral and psychological symptoms in Alzheimer’s disease patients
P750
Poster Presentations: P3
particularly those related to agitation, delusions, and nighttime behaviors.
P3-300
COMBINATION THERAPY OF CHOLINESTERASE INHIBITOR PLUS MEMANTINE FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN ALZHEIMER’S DISEASE PATIENTS
Cheol-Seung Shin, Seo-Gwang General Hospital, Gwang-ju, South Korea. Contact e-mail: [email protected] Background: To compare the effectiveness of combination therapy with cholinesterase inhibitors (ChEI) plus memantine in the treatment of aggression, agitation, and psychosis with older Alzheimer’s disease (AD) patients (age >75 years). Methods: We compared the clinical effects of combination therapy of cholinesterase inhibitors (ChEI) plus memantine (n¼50) in all AD patients with behavioral and psychological symptom of dementia (BPSD) (assessed by NPI baseline score). Primary efficacy measure: Neuropsychiatric Inventory (NPI); secondary efficacy measures: Clinical Global Impression (CGI), CohenMansfield Agitation Inventory (CMAI), Mini-Mental State Examination (MMSE) and instrumental activities of daily living (ADL). Results: The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores for 6 months. NPI scores decreased significantly from baseline to month 6 (P
Fig. 1. Neuropsychiatric inventory (NPI) scores from baseline to Week 6 (mean score, SD; ITT, LOCF)
Fig. 2. CMAI scores from baseline to Month 6 (mean score, SD; ITT, LOCF)
Table 1 Baseline Characteristics of Patients at Included Sites Characteristics
ChEI (N ¼ 50)
ChEI + Memantine (N¼50)
Female, N (%) Mean age (SD), years Mean duration of disease (SD), months Concomitant medication, n (%) NPI Score (total score) CMAI Score MMSE CGI (total score)
30 (60) 78.5 (5.6) 36.7 (25.4) 80 (100) 55.6 (14.5) 45.3 (17.6) 11 (4.38) 4.29 (0.98)
31 (62) 78.7 (5.2) 38.4 (23.5) 80 (100) 55.3 (17.4) 46.3 (16.7) 11 (4.52) 4.57(0.97)
Fig. 3. Instrumental ADL from baseline to Month 6 (mean score, SD; ITT, LOCF)
Poster Presentations: P3
particularly those related to agitation, delusions, and nighttime behaviors.
P3-300
COMBINATION THERAPY OF CHOLINESTERASE INHIBITOR PLUS MEMANTINE FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS IN ALZHEIMER’S DISEASE PATIENTS
Cheol-Seung Shin, Seo-Gwang General Hospital, Gwang-ju, South Korea. Contact e-mail: [email protected] Background: To compare the effectiveness of combination therapy with cholinesterase inhibitors (ChEI) plus memantine in the treatment of aggression, agitation, and psychosis with older Alzheimer’s disease (AD) patients (age >75 years). Methods: We compared the clinical effects of combination therapy of cholinesterase inhibitors (ChEI) plus memantine (n¼50) in all AD patients with behavioral and psychological symptom of dementia (BPSD) (assessed by NPI baseline score). Primary efficacy measure: Neuropsychiatric Inventory (NPI); secondary efficacy measures: Clinical Global Impression (CGI), CohenMansfield Agitation Inventory (CMAI), Mini-Mental State Examination (MMSE) and instrumental activities of daily living (ADL). Results: The addition of memantine resulted in stabilization of the Mini-Mental State Examination scores for 6 months. NPI scores decreased significantly from baseline to month 6 (P
Fig. 1. Neuropsychiatric inventory (NPI) scores from baseline to Week 6 (mean score, SD; ITT, LOCF)
Fig. 2. CMAI scores from baseline to Month 6 (mean score, SD; ITT, LOCF)
Table 1 Baseline Characteristics of Patients at Included Sites Characteristics
ChEI (N ¼ 50)
ChEI + Memantine (N¼50)
Female, N (%) Mean age (SD), years Mean duration of disease (SD), months Concomitant medication, n (%) NPI Score (total score) CMAI Score MMSE CGI (total score)
30 (60) 78.5 (5.6) 36.7 (25.4) 80 (100) 55.6 (14.5) 45.3 (17.6) 11 (4.38) 4.29 (0.98)
31 (62) 78.7 (5.2) 38.4 (23.5) 80 (100) 55.3 (17.4) 46.3 (16.7) 11 (4.52) 4.57(0.97)
Fig. 3. Instrumental ADL from baseline to Month 6 (mean score, SD; ITT, LOCF)